SH5-07

Item no.	HY-100494-1mg
Manufacturer	MedChem Express
CASRN	1456632-41-9
Amount	1 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Lineage Markers Neural Transcription Factors Targets for Rodent Neurosciences Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Breast Cancer Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Yue P,et al. Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. Cancer Res. 2016 Feb 1;76(3):652-63.
Smiles	O=C(NO)C1=CC=C(N(CC2=CC=C(C3CCCCC3)C=C2)C(CN(C)S(=O)(C4=C(F)C(F)=C(F)C(F)=C4F)=O)=O)C=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1456632-41-9
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	STAT
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	625.61
Product Description	SH5-07 is a hydroxamic acid based Stat3 inhibitor with an IC50 of 3.9 μM in in vitro assay[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 50 mg/mL (ultrasonic)
Manufacturer - Pathway	JAK/STAT Signaling; Stem Cell/Wnt
Isoform	STAT3
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100494-1mg-safety-datasheet.pdf